Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance
Science Advances · 2025
DOI: 10.1126/sciadv.ads9168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Matthew T Klope und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Drug Resistance, Malaria, Falciparum. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
For over two decades, artemisinin-based combination therapy (ACT) has been the standard of care for the treatment of uncomplicated falciparum malaria. However, artemisinin partial resistance (ART-R) is now prevalent in Southeast Asia and has emerged in eastern Africa, threatening ACT efficacy. Artefenomel, a synthetic 1,2,4-trioxolane, exhibits an extended pharmacokinetic exposure profile that predicts for efficacy against ART-R parasites. Unfortunately, the development of artefenomel was halted recently after almost a decade in the clinic. Here, we describe studies of an artefenomel-adjacent chemotype that combines potent in vitro activity against clinical ART-R parasites, an extended pharmacokinetic profile with single-exposure efficacy in a murine malaria model, and enhanced stability in human microsomes and hepatocytes. Overall, our studies reveal a heretofore underexplored trioxolane chemotype with the potential to address ART-R in a next-generation trioxolane development candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
- Dominican University of California, San Rafael, CA, USA.
- Departments of Chemistry and In Vivo Pharmacology, Tatara Therapeutics, San Francisco, CA, USA.
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- Advanced Light Source, Lawrence Berkeley National Laboratory and Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.
- Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA.
ORCID-Profile: Matthew T Klope, Shaun D Fontaine, Ryan L Gonciarz, Priyadarshini Jaishankar, Martin Okitwi, Nicholas S Settineri, Juan A Tapia, Aswathy Vinod, Jeremy N Burrows, Philip J Rosenthal, Adam R Renslo
Förderung
- NIGMS NIH HHS
Zitieren
APA
Klope, M. T., Talukder, P., Blank, B. R., Chelebieva, S., Chen, J., Fontaine, S. D., Gonciarz, R. L., Jaishankar, P., Lee, G. J., Legac, J., Mathur, V., Narayan, A., Okitwi, M., Orena, S., Settineri, N. S., Tapia, J. A., Taremwa, Y., Tumwebaze, P. K., Vinod, A., …, & Renslo, A. R. (2025). Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance. Science Advances. https://doi.org/10.1126/sciadv.ads9168
Vancouver
Klope MT, Talukder P, Blank BR, Chelebieva S, Chen J, Fontaine SD, et al. Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance. Science Advances. 2025. doi:10.1126/sciadv.ads9168
BibTeX
@article{Klope2025,
author = {Klope, Matthew T and Talukder, Poulami and Blank, Brian R and Chelebieva, Sevil and Chen, Jun and Fontaine, Shaun D and Gonciarz, Ryan L and Jaishankar, Priyadarshini and Lee, Grace J and Legac, Jennifer and Mathur, Vineet and Narayan, Avani and Okitwi, Martin and Orena, Stephen and Settineri, Nicholas S and Tapia, Juan A and Taremwa, Yoweri and Tumwebaze, Patrick K and Vinod, Aswathy and Burrows, Jeremy N and Rosenthal, Philip J and Cooper, Roland A and Renslo, Adam R},
title = {Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.ads9168}
}
EUVIMED